Roland Greinwald. Head of R&D at Dr. Falk Pharma GmbH. He leads the global collaboration for Dr. Falk with Prometheus to develop and commercialize PR600 (anti-CD30 Ligand antibody), Prometheus’ cell signaling program that targets a receptor of the tumor-necrosis factor superfamily for the treatment of IBD. Prior to Dr. Falk Pharma, Mr. Greinwald was previously a researcher at the University of Wuerzburg in the department of pharmaceutical biology. Mr. Greinwald has authored more than 180 scientific publications and has numerous patents supporting many inflammatory therapeutic drug candidates and formulations.
Brian G. Feagan, M.D. Gastroenterologist, epidemiologist and Senior Scientific Director at Alimentiv. He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 400 articles.
Dr. Targan is one of the founding members of Precision IBD, the predecessor of Prometheus Biosciences and is currently the Director of the Inflammatory Bowel and Immunobiology Research Institute at Cedars-Sinai Medical Center. Dr. Targan began his career at UCLA School of Medicine in 1978 and then moved his laboratories and practice in 1992 to establish the IBD Center at Cedars-Sinai. Dr. Targan has focused on identifying drivers of IBD pathogenesis, which in the context of such a genetically heterogeneous disease, involves numerous biologic and molecular pathways and comprises complex relationships between the intestinal microenvironment and the immune response. With over four decades of experience in treating IBD patients and over 300 peer-reviewed articles, Dr. Targan is a recognized leader in inflammatory bowel diseases. He was previously a co-founder of Santarus and Prometheus Laboratories.
Bruce E. Sands, M.D. is the head of the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai in New York, NY. He also serves as the Dr. Burrill B. Crohn’s Professor and Chief of Gastroenterology at Mount Sinai. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn’s & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital’s Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School. He is a fellow of the American College of Gastroenterology and the American Gastroenterological Association and is reviewer for the New England Journal of Medicine. Dr. Sands received his medical degree at Boston University School of Medicine and completed a residency in internal medicine at the Hospital of the University of Pennsylvania. He then completed clinical and research fellowships at the Massachusetts General Hospital. In 2001 Dr. Sands also earned a Master of Science in Epidemiology at Harvard School of Public Health.
Luisa Salter-Cid, Ph.D. currently serves as the Chief Scientific Officer of Gossamer Bio where she oversees a Research team focused on bringing Immunology-based innovative medicines up to IND filling. Prior to joining Gossamer, Dr. Salter-Cid spent 13 years at Bristol Myers Squibb where she held several positions including Vice President and Head of Immunology, small molecule Immuno-Oncology and Genomics Discovery. In this position, she oversaw several biology groups that focused on target validation and development of innovative biologic and small-molecule therapeutics to address significant unmet needs in autoimmune diseases and cancer. During her time at BMS, Dr. Salter-Cid led teams that advanced more than 20 compounds into clinical development. She was also Chair of the Immunoscience Target Science Team (TST) and a core member of several executive committees focused on strategy, development and external collaborations. Prior to joining BMS, she was a Senior Project Leader at La Jolla Pharmaceuticals where she led discovery projects. She also held positions at Genset Corp and Johnson & Johnson.
Dr. McGovern is a gastroenterologist and preeminent geneticist in the IBD field. Dr. McGovern completed his GI fellowship and obtained a PhD in complex disease genetics at the University of Oxford, England before moving to Cedars-Sinai. Dr. McGovern is the Director of Translational Medicine at Cedars, co-Director of the Cedars-Sinai IBD repository (MIRIAD) and IBD Database and was recently appointed the Director of Precision Health at Cedars-Sinai. Dr. McGovern serves on both the Steering Committee of the NIDDK IBD Genetics Consortium, and on the Management Committee of the International IBD Genetics Consortium. Dr. McGovern is one of the founding members of Precision IBD, the predecessor of Prometheus Biosciences and serves as the consulting geneticist and provides input on the patient selection criteria.
Donna Griebel, M.D. is former Director of the Division of Gastroenterology and Inborn Errors Products (DGIEP) in the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA). As acting Director, she regulated Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and Biologics Licensing Applications (BLAs) for drugs and therapeutics biologics intended for the treatment and prevention of gastrointestinal, hepatic and nutritional disorders and inborn error of metabolism. In her prior position, Dr. Griebel was Deputy Director of the Division of Reproductive and Urologic products where she oversaw the safety and efficacy of drugs and therapeutic biologics aimed to improving reproductive and urologic health. She has extensive regulatory experience in drug development and served on CDER’s Medical Policy Council (MPC) and the MPC’s Subcommittee on Safety Outcome Trials.
Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became a tenured Professor of Medicine and Adjunct Professor of Surgery at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. He was previously a co-founder of Santarus working directly with Scott Glenn, Stephan Targan & Gerry Proehl. Dr. Sandborn has published over 720 peer reviewed articles and is a member of the editorial board for the New England Journal of Medicine.